Scholars Central

Case reportPublished 28 Oct 2024

Melanonychia is an Adverse Effect of TNF Inhibitors (Adalimumab) in Psoriatic Arthritis Patient: A Case Report

Authors: Tahir Hussein Alsaadawi

Rheumatology: Current Research

Volume 14 · Issue 6 · Pages 1–3

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Introduction: Melanonychia, derived from the Greek terms "melas" (black) and "onyx" (nail), is characterized by brown-black discoloration of the nail plate, primarily due to melanin production. This condition can arise from two mechanisms: Melanocytic activation and melanocyte proliferation. Case presentation: A fully human monoclonal antibody targeting Tumor Necrosis Factor (TNF), adalimumab is used to treat several immune-mediated inflammatory diseases, including rheumatoid arthritis, psoriatic arthritis, and Crohn's disease. Skin-related adverse effects account for approximately 25% of all reported side effects of anti- TNF therapies, which may only become apparent in clinical practice despite thorough preclinical studies. Results: This case report suggests that adjusting the frequency of adalimumab therapy can effectively manage adverse effects like melanonychia while retaining the drug's therapeutic benefits. Modifying the dosing schedule led to significant improvements in nail pigmentation. Discussion: The findings are consistent with existing literature, which documents skin-related adverse effects from TNF inhibitors, including melanonychia. This aligns with studies that highlight the potential for TNF antagonists to induce immune-mediated reactions affecting melanocyte activity. Conclusion: The case of adalimumab-induced melanonychia underscores the need for clinicians to remain vigilant for a broad range of potential side effects. Further research is necessary to better understand the safety profile of biologic therapies and to recognize uncommon adverse effects like melanonychia

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Rheumatology: Current Research.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalRheumatology: Current Research
  • SubjectRheumatology
  • SubjectOrthopaedics
  • BylineArticles whose byline prints “Tahir Hussein Alsaadawi”